Solid tumor biotech Atreca files for a $100 million IPO

Shutterstock photo

Atreca, a preclinical biotech developing immunotherapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The Redwood City, CA-based company was founded in 2010 and plans to list on the Nasdaq under the symbol BCEL. Atreca filed confidentially on April 24, 2019. Cowen, Evercore ISI and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Solid tumor biotech Atreca files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?